Jun 30, 2025 7:30 am EDT Abeona Therapeutics® added to Membership of U.S. Small-cap Russell 2000® Index and Broad-market Russell 3000® Index
Jun 24, 2025 7:30 am EDT Abeona Therapeutics® Announces Publication in The Lancet of Phase 3 VIITAL™ Study Data in Recessive Dystrophic Epidermolysis Bullosa
Jun 2, 2025 7:30 am EDT Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 30, 2025 8:46 am EDT Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference
May 15, 2025 7:30 am EDT Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
May 14, 2025 8:07 am EDT UPDATE -- Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYN™ Gene Therapy to Treat Wounds in Painful Skin Disorder
May 14, 2025 7:30 am EDT Abeona Therapeutics® and Lurie Children's Open First Center for ZEVASKYNTM Gene Therapy to Treat Wounds in Painful Skin Disorder
May 12, 2025 7:30 am EDT Abeona Therapeutics® Enters into Agreement to Sell Priority Review Voucher for $155 Million
May 7, 2025 4:59 pm EDT Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 29, 2025 6:00 am EDT U.S. FDA Approves ZEVASKYN™ (prademagene zamikeracel), the First and Only Cell-Based Gene Therapy for Patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB)
